废旧电子材料回收利用现状及发展展望

随着科学技术的进步，各类电子产品已经成为人们生活中不可缺少的组成部分，而其发展和普及的背后，我们将面临越来越多淘汰的废旧电子产品对环境带来的压力。与此同时，各类资源的短缺也需要从这些富含众多金属元素的废旧电子材料中找出解决办法。从废旧电子材料回收的紧迫性和必要性出发，分别介绍了目前国内外回收技术的现状及发展方向，并介绍了模型在回收技术发展和实际应用中可以起到的辅助作用。     

生产型组织初始环境评审中环境因素的识别评价

环境因素的识别与评价是环境管理体系建立和实施的关键，生产型企业在初始环境评审时可以工程分析为重点，结合对正常和异常情况的分析，对生产过程和各部门涉及的环境影响进行全面分析，从而确定环境因素。在评价重要环境因素时，可先根据企业对外环境排放的接口情况、环境影响情况，结合商业方面的考虑制定重要环境因素评价准则，再利用评价准则评价出重要环境因素。     

膜生物反应器膜污染的水力学控制实验研究

叙述了膜污染是影响膜-生物反应器处理技术推广应用的关键因素，采用水动力学方法是控制膜污染的有效方法。在不同污泥浓度条件下。对不同曝气强度下膜污染的发展速率及其形成机理进行了试验研究，研究结果表明：对应于不同污泥浓度均存在一个经济曝气强度，其大小随污泥浓度升高呈线性增加，膜生物反应器在经济曝气强度条件下运行可控制膜污染的发展；并从理论上推导出一个临界污泥浓度，其值为5．15g／L。对应于临界污泥浓度，并且污泥絮体在膜面可形成比较稳定的动态膜，膜过滤压差上升的速率最慢，膜生物反应器在此临界污泥浓度条件下运行膜污染发展最为缓慢。     

“赛力奇”的致突变性研究

选用Ａｍｅｓ试验、小鼠骨髓细胞微核实验和小鼠显性致死突变试验对新型食品添加剂“赛力奇”的致突变性进行了检验。结果表明：三项试验的结果均生。根据国家《食品安全性毒理学评价程序（试行）》的规定，认为“赛力奇”无致突变性。     

An accessory marker derived from chromosome 20 and its co-existence with a mosaic trisomy 20 cell line

We report a 16-month-old boy with delayed psychomotor development, dysmorphic features, and failure to thrive. He had a mosaic karyotype detected prenatally: mos 46,XY/47,XY,+r(20)/47,XY,+20. After birth, the abnormal cell lines were confirmed in a number of tissues. The small ring chromosome was identified using fluorescence in situ hybridization as derived from chromosome 20. We compared our patient with previously reported cases of mosaic trisomy 20 detected prenatally and associated with an abnormal phenotype. In an attempt to characterize an r(20) syndrome, we also compared our case with two similar reports in the literature.     

Thyroid antibodies are not a risk factor for pregnancies with down syndrome

The observation that thyroid disease is frequent in mothers of children with Down syndrome (DS) has suggested that maternal thyroid antibodies could be a factor predisposing to trisomy 21 in their offspring. In this study, the incidences of thyroglobulin (Tg) and thyroid peroxidase (TPO) antibodies were analysed with a sensitive solid-phase immunosorbent radioassay in sera from 29 mothers giving birth to children with trisomy 21 and 87 control mothers. The serum samples were collected at delivery. There was no statistical difference regarding the proportion of thyroid antibodies (against Tg and/or TPO) in the two groups. Thyroid antibodies were detected in 6/29 (20.7 per cent) of the DS mothers and in 23/87 (26.4 per cent) of the control mothers. Among the women with thyroid antibodies, 4/6 (66.7 per cent) of the DS mothers and 12/23 (52 per cent) of the control mothers had antibodies against both Tg and TPO. There was no increase in the relative risk of having a child with DS if the titre of either Tg or TPO antibodies or both were positive, i.e. ≥ 1/5. The results indicate that the presence of thyroid antibodies in the serum of a pregnant woman has no prognostic value for the birth of an infant with DS.